Eribulin - Eisai Co Ltd

Drug Profile

Eribulin - Eisai Co Ltd

Alternative Names: B-1939; B-1939 mesylate; E-7386; E-7389; ER-086526; Eribrin; Eribulin mesylate; Halaven; NSC-707389

Latest Information Update: 08 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eisai Co Ltd; Harvard University
  • Developer Asan Medical Center; Big Ten Cancer Research Consortium; Eisai Co Ltd; Emory University; Icahn School of Medicine at Mount Sinai; Merck & Co; National Cancer Center Hospital East; National Cancer Institute (USA); Pfizer; PIQUR Therapeutics
  • Class 2 ring heterocyclic compounds; Antineoplastics; Cyclic ethers; Furans; Ketones; Macrocyclic compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Soft tissue sarcoma
  • Phase III Non-small cell lung cancer
  • Phase II Ewing's sarcoma; Haemangioendothelioma; Haemangiosarcoma
  • Phase I/II Bladder cancer; Solid tumours
  • Phase I Ovarian cancer; Urogenital cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 19 Sep 2018 Eisai terminates the phase II trial ALERT trial due to slow patient recruitment in Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom (IV) (NCT02681523)
  • 12 Jun 2018 Phase-I clinical trials in Urogenital cancer (Combination therapy, Metastatic disease, Late-stage disease) in USA (IV) (NCT03502681)
  • 01 Jun 2018 Efficacy data from a phase II trial in Breast cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018) (ADNM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top